{"id":32430,"date":"2023-06-14T07:00:11","date_gmt":"2023-06-14T05:00:11","guid":{"rendered":"https:\/\/www.ipsen.com\/qa-us\/?post_type=press_release&p=32430"},"modified":"2023-06-26T10:47:49","modified_gmt":"2023-06-26T08:47:49","slug":"ipsen-announces-u-s-fda-submission-acceptance-of-its-supplemental-new-drug-application-for-onivyde-regimen-in-first-line-metastatic-pancreatic-ductal-adenocarcinoma","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-announces-u-s-fda-submission-acceptance-of-its-supplemental-new-drug-application-for-onivyde-regimen-in-first-line-metastatic-pancreatic-ductal-adenocarcinoma\/","title":{"rendered":"Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma"},"content":{"rendered":"\n